GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Mirabegron (Myrbetriq)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Myrbetriq

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Myrbetriq - product and source limitations

Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Myrbetriq - product and source limitations

Handbook source

Renal Drug Handbook, fifth edition

Choose a product and source Product label GlobalRPh RX passage All evidence
Product / population
Historical 2019 reference; renal bands retain the book's own method labels.
Renal measure
Not specified; verify before use
Source revision
Not established
Retrieved
2026-09-05 (not the revision date)

The selected U.S. adult tablet label does not recommend treatment below eGFR 15 or on hemodialysis. The book's below-15 and dialysis doses are historical source differences, not endorsed replacement protocols.

Historical renal bands

GFR 30-60 mL/min: usual dose, or 25 mg with CYP3A inhibitors. At 15-29, the book lists 25 mg daily and avoidance with CYP3A inhibitors. It also lists 25 mg below 15, with the same interaction caution.

Historical renal-replacement comments

The book considers removal unlikely across APD/CAPD, HD, high-flux HDF and CAV/VVHD, referring the first three to <15 and CAV/VVHD to 15-29.

Source revision: Not established | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source:

Scope: Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Myrbetriq - labeled renal guidance

Source retrieved 2026-11-07 - confirm current applicability

Use is not recommended / excluded in the named dialysis population; not a dialysis dose

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Myrbetriq - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: Use is not recommended / excluded in the named dialysis population; not a dialysis dose

Mirabegron (Myrbetriq), adult oral extended-release tablets for overactive bladder

Renal method: MDRD estimate, mL/min/1.73 m2
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Myrbetriq - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Mirabegron (Myrbetriq), adult oral extended-release tablets for overactive bladder

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Myrbetriq - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Myrbetriq - product and source limitations

Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.

How to use this: Apply only to the stated formulation, indication and renal population.

Myrbetriq - labeled renal guidanceMyrbetriq - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMYRBETRIQ (mirabegron) extended-release tabletsMyrbetriq - labeled renal guidanceMyrbetriq - selected RX renal passageRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The handbook includes historical dosing below GFR 15 and during dialysis. The selected U.S. adult tablet label does not recommend use below eGFR 15 or during hemodialysis; the handbook is not an override.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

Dosing Information: The recommended starting dose of Myrbetriq is 25 mg once daily with or without food. Myrbetriq 25 mg is effective within 8 weeks. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily. Myrbetriq should be taken with water, swallowed whole and should not be chewed, divided, or crushed.

Dose Adjustments in Specific Populations: The daily dose of Myrbetriq should not exceed 25 mg once daily in the following populations: Patients with severe renal impairment (CLcr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2). Patients with moderate hepatic impairment (Child-Pugh Class B).

Myrbetriq is not recommended for use in patients with end stage renal disease (ESRD), or in patients with severe hepatic impairment (Child-Pugh Class C).

GRPH-general-mirabegron-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

MYRBETRIQ (mirabegron) extended-release tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adult overactive bladder; extended-release tablets only, not pediatric granules.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Adult oral regimen

Start 25 mg once daily. An increase to 50 mg daily may be made after 4-8 weeks when indicated. Tablets and granules are not interchangeable milligram-for-milligram.

general-mirabegron:dm-ba9e9e15-e666-4c56-9271-2e24739cfa2d-1 · Source locator: 2.1; 2.2

Labeled renal limits

Table 2 uses MDRD eGFR in mL/min/1.73 m2. At 30-89, start 25 mg/day and allow at most 50 mg/day. At 15-29, both starting and maximum doses are 25 mg/day. Below 15 or during hemodialysis, use is not recommended.

general-mirabegron:dm-ba9e9e15-e666-4c56-9271-2e24739cfa2d-2 · Source locator: 2.4, Table 2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d
Retrieved
2026-09-05
Exact label title
MYRBETRIQ (mirabegron) extended-release tablets
DailyMed Set ID
ba9e9e15-e666-4c56-9271-2e24739cfa2d
Labeler
Astellas Pharma US, Inc.
DailyMed page updated
2024-08-01
FDA application
NDA marketing category
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
81d3ebd98ae2d7b043b99b34bb085976e95e561b5ec37758301ae7fefa890617
Official

Myrbetriq - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Mirabegron (Myrbetriq), adult oral extended-release tablets for overactive bladder

Renal method: MDRD estimate, mL/min/1.73 m2
Source date: DailyMed SPL version 17, effective 2024-08-01; posted Aug 20, 2024
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: Use is not recommended / excluded in the named dialysis population; not a dialysis dose

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.4, adult Table 2 and 8.6

Limits that apply to these rows

Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.

Adult renal dosing in this source
Adult eGFR (mL/min/1.73 m2)Oral starting dose once dailyMaximum once daily
30-8925 mg50 mg
15-2925 mg25 mg
<15 or on dialysisUse not recommendedUse not recommended
Read the retained text before reformatting

At eGFR 30-89, start 25 mg once daily, maximum 50 mg daily. At 15-29, use 25 mg daily as both starting dose and maximum. Below 15 or on dialysis, use is not recommended. Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.

RDM73-myrbetriq-official-1 · Source locator: Renal guidance: 2.4, adult Table 2 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d
Retrieved
2026-11-07
Renal-function method
MDRD estimate, mL/min/1.73 m2
Source date/version
DailyMed SPL version 17, effective 2024-08-01; posted Aug 20, 2024
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d4f6b6fd71327d5eb85400e46ba449fa3d0e040ce8222d7c1bbd6718258767b6
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Myrbetriq - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Mirabegron (Myrbetriq), adult oral extended-release tablets for overactive bladder

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror places eGFR below 15 and dialysis outside recommended use and gives separate pediatric tables.

RDM73-myrbetriq-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/myrbetriq-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
877dc4d76b53b1f275be3525e7a2ca883e4db9b8514e7790836a17bb6dd9ea1b
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal bands

GFR 30-60 mL/min: usual dose, or 25 mg with CYP3A inhibitors. At 15-29, the book lists 25 mg daily and avoidance with CYP3A inhibitors. It also lists 25 mg below 15, with the same interaction caution.

general-mirabegron:rdh5-663-1 · Source locator: Dose in renal impairment

Historical renal-replacement comments

The book considers removal unlikely across APD/CAPD, HD, high-flux HDF and CAV/VVHD, referring the first three to <15 and CAV/VVHD to 15-29.

general-mirabegron:rdh5-663-2 · Source locator: Dose in renal replacement

Source-specific limits

The selected U.S. adult tablet label does not recommend treatment below eGFR 15 or on hemodialysis. The book's below-15 and dialysis doses are historical source differences, not endorsed replacement protocols.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 663; PDF page 682
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
7fdc14e013014fab28634985209346ad764d335ccd9f949373e0b3a0fa685365

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 15
Local text SHA-256
2f142a1e96e1f90a98e215a688e5d974a0be2900f120c0b521581c7eed3748fe
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top